A Phase 2 interventional study of TNX-102 SL in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 334th largest by enrollment of the 1,491 interventional ones that give a count, is one of 59 that started in 2015, is one of 168 in phase 2, and was the 614th registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Anthony Vesco · Sites in United States
Ages 8–18
Transcend Therapeutics · Sites in United States
Ages 18+
COMPASS Pathways · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,664 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 132 · Phase 2 234 · Phase 3 95 · Phase 4 90
First in 1991; this study’s year is marked. 59 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 69 across 2,199 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 65 across the 1,491 interventional studies, 107 across the 165 observational. Of the 1,135 that completed or were terminated, 491 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 1,664 have an industry lead sponsor. The 10 most frequent:
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Tonix Pharmaceuticals, Inc. has 7 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
154 of the studies in Stress Disorders, Post-Traumatic with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT04877093Phase 3Wake Forest University Health SciencesRepurposing Low-Dose Clonidine for PTSD in Veterans | 2027-03-31 |
| NCT06273527Phase 3University of California, San DiegoEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) | 2027-06-01 |
| NCT07217795University of Rhode IslandRecovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building | 2026-11 |
| NCT04585685Christal L BadourHealthy Recovery After Trauma Study | 2026-11 |
Add all 154 to your calendar (.ics) → With an account.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition. Patients recruited into this trial are those who have successfully completed the double-blind study, TNX-CY-P201 (AtEase Study) [NCT02277704]. Patients will not be made aware of the therapy they received during the double-blind study.
The study will consist of 4 clinic visits, including Screening/Baseline Visit 1 (Day 0, which is anticipated to be the same date as the final visit in the lead-in P201 study) and visits after 2, 6 and 12 weeks of treatment. The previous requirements in the lead-in study for refraining from the use of certain concomitant medications and trauma-focused psychotherapies will be relaxed. Patients may continue to take rescue therapy for sleep, as appropriate, or they may utilize other medications as needed to help them sleep, per the judgment of the investigator.
Eligible patients who provide written informed consent will take one TNX-102 SL tablet daily at bedtime sublingually (under the tongue) for 12 weeks. All patients will be assigned to receive tthe same dosage of TNX-102 SL, regardless of their treatment assignment in the lead-in study. No patients, investigators, or study staff will know the assigned study treatment from the lead-in study, P201, at the time of entry into the extension study. Patient data collected at the Week 12 visit (Visit 9) in the lead-in P201 study will be used as one of the baseline values for this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TNX-102 SL taken daily at bedtime for 12 weeks
Drug: TNX-102 SL
1x 2.8mg TNX-102 SL Sublingual tablet
Also known as: cyclobenzaprine HCI
Newly Treatment Emergent Adverse Events
Number of patients with new treatment emergent AEs since completing lead-in study
Time frame: Week 12
Total CAPS-5 (Clinician Administered PTSD Scale (for Diagnostic and Statistical Manual of Mental Disorders Version 5)
Changes in total CAPS-5 score from baseline in lead-in study and since baseline in this study. CAPS-5 score ranges from 0-80 with lower scores indicating less sever PTSD symptoms.
Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12
Response Rates a in Total CAPS-5 Score
≥30% decrease in Total CAPS-5 score from baseline in lead-in study and since baseline in this study. Lower scores on CAPS-5 indicate less severe PTSD symptoms.
Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P201 Week 12
CAPS-5 Cluster Score Items
Changes from baseline in lead-in study and since baseline in this study in item scores, including * intrusion symptoms (Criterion B) - Score ranges from 0 to 20. * CAPS-5 item 2. (B-2) (unpleasant dreams related to the trauma) - Score ranges from 0 to 4 * persistent avoidance (Criterion C) - Score ranges from 0 to 8 * negative cognitions and mood (Criterion D) - Score ranges from 0 to 28 * arousal and reactivity (Criterion E) - Score ranges from 0 to 24 Lower scores indicate less severe symptoms on all items
Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12
Montgomery-Asberg Depression Rating Scale
Changes from baseline in lead-in study and since baseline in this study in MADRS. Score ranges from 0 to 60. Lower scores indicate less severe depression symptoms.
Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12
PROMIS (Patient -Reported Outcome Measurement Information System)
Changes from baseline in lead-in study and since baseline in this study in PROMIS scores. Raw scores are converted to T-scores with mean of 50 and standard deviation of 10 using published conversion tables based on the US population. * Fatigue T-score ranges from 33.1 to 77.8. Lower scores indicate less fatigue * Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance * Global Physical Health T-score ranges from 16.2 to 67.7. Lower scores indicate better physical health * Global Mental Health T-score ranges from 21.2 to 67.6. Lower scores indicate better mental health
Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12
| Milestone | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg |
|---|---|---|---|
| Started | 58 | 64 | 37 |
| Completed | 47 | 49 | 32 |
| Not completed | 11 | 15 | 5 |
Number of patients with new treatment emergent AEs since completing lead-in study
| Participants | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg |
|---|---|---|---|
| Newly Treatment Emergent Adverse Events | 37 | 20 | 14 |
Changes in total CAPS-5 score from baseline in lead-in study and since baseline in this study. CAPS-5 score ranges from 0-80 with lower scores indicating less sever PTSD symptoms.
| units on a scale | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg |
|---|---|---|---|
| Change from P201 Baseline to P202 Week 12 | -25.3 ± 2.55 | -25.6 ± 2.59 | -26.9 ± 2.80 |
| Change from P202 Baseline to P202 Week 12 | -4.9 ± 1.80 | -4.8 ± 1.82 | -3.7 ± 2.01 |
≥30% decrease in Total CAPS-5 score from baseline in lead-in study and since baseline in this study. Lower scores on CAPS-5 indicate less severe PTSD symptoms.
| Participants | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg |
|---|---|---|---|
| Patients with ≥30% decrease in Total CAPS-5 score from P201 Day 1 to P202 Week 12 | 43 | 47 | 30 |
| Patients with ≥30% decrease in Total CAPS-5 score from P202 Day 1 to P202 Week 12 | 20 | 24 | 13 |
Changes from baseline in lead-in study and since baseline in this study in item scores, including * intrusion symptoms (Criterion B) - Score ranges from 0 to 20. * CAPS-5 item 2. (B-2) (unpleasant dreams related to the trauma) - Score ranges from 0 to 4 * persistent avoidance (Criterion C) - Score ranges from 0 to 8 * negative cognitions and mood (Criterion D) - Score ranges from 0 to 28 * arousal and reactivity (Criterion E) - Score ranges from 0 to 24 Lower scores indicate less severe symptoms on all items
| units on a scale | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg |
|---|---|---|---|
| Change from P201 Day 1 to P202 Week 12 in Criterion B | -7.7 ± 0.82 | -7.4 ± 0.82 | -7.7 ± 0.91 |
| Change from P202 Day 1 to P202 Week 12 in Criterion B | -1.9 ± 0.66 | -1.5 ± 0.66 | -1.4 ± 0.74 |
| Change from P201 Day 1 to P202 Week 12 in Item B-2 | -1.3 ± 0.23 | -1.4 ± 0.24 | -1.4 ± 0.26 |
| Change from P202 Day 1 to P202 Week 12 in Item B-2 | -0.3 ± 0.20 | -0.4 ± 0.21 | -0.2 ± 0.23 |
| Change from P201 Day 1 to P202 Week 12 in Criterion C | -3.1 ± 0.45 | -3.2 ± 0.45 | -3.1 ± 0.50 |
| Change from P202 Day 1 to P202 Week 12 in Criterion C | -0.4 ± 0.38 | -0.5 ± 0.39 | -0.5 ± 0.42 |
| Change from P201 Day 1 to P202 Week 12 in Criterion D | -7.6 ± 1.10 | -8.4 ± 1.12 | -9.1 ± 1.22 |
| Change from P202 Day 1 to P202 Week 12 in Criterion D | -1.1 ± 0.85 | -1.8 ± 0.85 | -1.4 ± 0.95 |
| Change from P201 Day 1 to P202 Week 12 in Criterion E | -6.8 ± 0.83 | -6.4 ± 0.84 | -7.1 ± 0.91 |
| Change from P202 Day 1 to P202 Week 12 in Criterion E | -1.4 ± 0.62 | -0.9 ± 0.62 | -0.8 ± 0.69 |
Changes from baseline in lead-in study and since baseline in this study in MADRS. Score ranges from 0 to 60. Lower scores indicate less severe depression symptoms.
| units on a scale | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg |
|---|---|---|---|
| Change from P201 Day 1 to P202 Week 12 | -8.1 ± 1.53 | -9.3 ± 1.57 | -9.9 ± 1.66 |
| Change from P202 Day 1 to P202 Week 12 | 0.1 ± 1.28 | -1.1 ± 1.30 | -2.1 ± 1.40 |
Changes from baseline in lead-in study and since baseline in this study in PROMIS scores. Raw scores are converted to T-scores with mean of 50 and standard deviation of 10 using published conversion tables based on the US population. * Fatigue T-score ranges from 33.1 to 77.8. Lower scores indicate less fatigue * Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance * Global Physical Health T-score ranges from 16.2 to 67.7. Lower scores indicate better physical health * Global Mental Health T-score ranges from 21.2 to 67.6. Lower scores indicate better mental health
| T-score | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg |
|---|---|---|---|
| Change from P201 Day 1 to P202 Week 12 in PROMIS Sleep Disturbance T-scores | -10.4 ± 2.50 | -12.2 ± 2.58 | -14.3 ± 2.75 |
| Change from P202 Day 1 to P202 Week 12 in PROMIS Sleep Disturbance T-scores | 0.7 ± 2.36 | 0.4 ± 2.40 | -3.1 ± 2.60 |
| Change from P201 Day 1 to P202 Week 12 in PROMIS Fatigue T-scores | -5.6 ± 2.05 | -6.4 ± 2.08 | -8.0 ± 2.26 |
| Change from P202 Day 1 to P202 Week 12 in PROMIS Fatigue T-scores | 0.9 ± 1.78 | 1.1 ± 1.79 | -0.4 ± 1.93 |
| Change from P201 Day 1 to P202 Week 12 in PROMIS Global Mental Health T-scores | 7.1 ± 1.76 | 7.1 ± 1.79 | 10.1 ± 1.95 |
| Change from P202 Day 1 to P202 Week 12 in PROMIS Global Mental Health T-scores | 0.5 ± 1.50 | 0.2 ± 1.53 | 1.8 ± 1.67 |
| Change from P201 Day 1 to P202 Week 12 in PROMIS Global Physical Health T-scores | 3.1 ± 1.50 | 3.2 ± 1.53 | 5.8 ± 1.66 |
| Change from P202 Day 1 to P202 Week 12 in PROMIS Global Physical Health T-scores | -0.7 ± 1.18 | -0.2 ± 1.20 | 1.7 ± 1.30 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo- TNX-102 SL 2.8 mg | 0/54 (0%) | 0/54 (0%) | 29/54 (53.7%) |
| TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | 0/60 (0%) | 0/60 (0%) | 7/60 (11.7%) |
| TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg | 0/35 (0%) | 0/35 (0%) | 3/35 (8.6%) |
| Event | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg |
|---|---|---|---|
| Hypoaesthesia OralGastrointestinal disorders | 22/54 | 3/60 | 2/35 |
| Paraesthesia OralGastrointestinal disorders | 9/54 | 1/60 | 0/35 |
| Product Taste AbnormalProduct Issues | 3/54 | 0/60 | 0/35 |
| SomnolenceNervous system disorders | 2/54 | 3/60 | 1/35 |
Numbers are only reported for the safety population, which includes all patients who received at least one dose of investigational product under this protocol.
| Age, Continuous(years) | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg | Total |
|---|---|---|---|---|
| Mean | 33.1 ± 7.00 | 35.8 ± 8.22 | 35.4 ± 9.27 | 34.7 ± 8.11 |
| Sex: Female, Male(Participants) | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 3 | 10 |
| Male | 50 | 57 | 32 | 139 |
| Ethnicity (NIH/OMB)(Participants) | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 11 | 8 | 5 | 24 |
| Not Hispanic or Latino | 43 | 52 | 30 | 125 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 3 | 1 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 16 | 8 | 33 |
| White | 36 | 41 | 25 | 102 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 4 | 1 | 2 | 7 |
| Region of Enrollment(participants) | Placebo- TNX-102 SL 2.8 mg | TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg | TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg | Total |
|---|---|---|---|---|
| United States | 54 | 60 | 35 | 149 |
Ran from Apr 2015 to primary completion in May 2016, 13 months.
Results were first posted in Feb 2025, 8 years 8 months after primary completion. A results delay was requested in Oct 2017.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 13 months is below that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine
Stress Disorders, Post-Traumatic →